Sonoma Pharmaceuticals Inc (SNOA) Stock Price, Quote & News

Company Profile

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 800 759 9305

Website: sonomapharma.com

Address:

5445 Conestoga Court, Suite 150, Boulder, United States

MicroTrader69 Jun. 27 at 10:26 PM

$SNOA darn, gonna miss my date by a month

1 · Reply

noname10000 Jun. 27 at 12:30 PM

$SNOA clossr amd closer to the d day

0 · Reply

noname10000 Jun. 26 at 5:43 PM

$SNOA wtf is selling 1 share????? 2 shares.. insane

0 · Reply

noname10000 Jun. 26 at 1:51 PM

$SNOA lets make it great

0 · Reply

noname10000 Jun. 26 at 1:51 PM

$SNOA time.for some news guys

0 · Reply

Love_To_Learn Jun. 26 at 12:42 PM

$SNOA will need u shortly

0 · Reply

noname10000 Jun. 23 at 1:49 PM

$SNOA just an idiot sold now wants to buy it back lol

0 · Reply

noname10000 Jun. 20 at 1:40 PM

$SNOA give some news

0 · Reply

noname10000 Jun. 20 at 1:33 PM

$SNOA nice

0 · Reply

kellyc09 Jun. 18 at 6:48 PM

$SNOA Forgot I even owned this stock it has been so bad.

2 · Reply

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results

Apr 22, 2025, 4:01 PM EDT - 2 months ago

Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain

Mar 10, 2025, 4:01 PM EDT - 3 months ago

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

Feb 25, 2025, 4:01 PM EST - 4 months ago

Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando

Feb 5, 2025, 4:05 PM EST - 5 months ago

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results

Dec 5, 2024, 8:30 AM EST - 7 months ago

Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices

Nov 21, 2024, 4:06 PM EST - 7 months ago

Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

Nov 11, 2024, 4:20 PM EST - 8 months ago

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel

Nov 7, 2024, 8:45 AM EST - 8 months ago

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results

Oct 31, 2024, 4:01 PM EDT - 8 months ago

Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf

Oct 22, 2024, 8:35 AM EDT - 8 months ago

Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada

Oct 21, 2024, 4:01 PM EDT - 8 months ago

Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences

Sep 19, 2024, 8:30 AM EDT - 10 months ago

Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Sep 17, 2024, 8:30 AM EDT - 10 months ago

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

Sep 11, 2024, 8:30 AM EDT - 10 months ago

Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line

Aug 28, 2024, 6:10 AM EDT - 10 months ago

Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock

Aug 26, 2024, 8:30 AM EDT - 10 months ago

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff

Aug 21, 2024, 8:45 AM EDT - 11 months ago

Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States

Aug 8, 2024, 4:10 PM EDT - 11 months ago

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine

Jun 17, 2024, 5:00 PM EDT - 1 year ago

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results

May 9, 2024, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections

Mar 28, 2024, 4:01 PM EDT - 1 year ago

Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences

Mar 27, 2024, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals

Feb 8, 2024, 4:10 PM EST - 1 year ago

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results

Jan 23, 2024, 7:30 AM EST - 1 year ago

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use

Jan 9, 2024, 9:15 AM EST - 1 year ago

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network

NBY

Nov 13, 2023, 4:10 PM EST - 1 year ago

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results

Nov 3, 2023, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference

Oct 26, 2023, 9:10 AM EDT - 1 year ago

Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock

Aug 15, 2023, 7:30 AM EDT - 2 years ago

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board

Jun 22, 2023, 7:30 AM EDT - 2 years ago

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results

Jun 9, 2023, 5:05 PM EDT - 2 years ago

Sonoma Pharmaceuticals Shares Soar 44% After Introducing New Product

Jun 8, 2023, 4:01 PM EDT - 2 years ago

Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

Apr 11, 2023, 7:30 AM EDT - 2 years ago

Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care

Mar 28, 2023, 4:15 PM EDT - 2 years ago

Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia

Mar 2, 2023, 7:30 AM EST - 2 years ago

Sonoma Pharmaceuticals and MicroSafe Group Announce New EPA Claims and Green Seal Certification for Nanocyn(R) Hospital-Grade Disinfectant

Feb 14, 2023, 4:30 PM EST - 2 years ago

Sonoma Pharmaceuticals Reports Third Quarter 2023 Financial Results

Jan 31, 2023, 7:30 AM EST - 2 years ago

Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea

Jan 25, 2023, 7:30 AM EST - 2 years ago

Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products

Jan 4, 2023, 7:30 AM EST - 2 years ago

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas

Nov 14, 2022, 4:15 PM EST - 2 years ago

Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial Results

Oct 27, 2022, 4:01 PM EDT - 2 years ago

Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States

Oct 6, 2022, 4:15 PM EDT - 2 years ago

Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany

Aug 11, 2022, 4:30 PM EDT - 3 years ago

Sonoma Pharmaceuticals Reports First Quarter 2023 Financial Results

Aug 2, 2022, 4:30 PM EDT - 3 years ago

Sonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical Supply

MicroTrader69 Jun. 27 at 10:26 PM

$SNOA darn, gonna miss my date by a month

1 · Reply

noname10000 Jun. 27 at 12:30 PM

$SNOA clossr amd closer to the d day

0 · Reply

noname10000 Jun. 26 at 5:43 PM

$SNOA wtf is selling 1 share????? 2 shares.. insane

0 · Reply

noname10000 Jun. 26 at 1:51 PM

$SNOA lets make it great

0 · Reply

noname10000 Jun. 26 at 1:51 PM

$SNOA time.for some news guys

0 · Reply

Love_To_Learn Jun. 26 at 12:42 PM

$SNOA will need u shortly

0 · Reply

noname10000 Jun. 23 at 1:49 PM

$SNOA just an idiot sold now wants to buy it back lol

0 · Reply

noname10000 Jun. 20 at 1:40 PM

$SNOA give some news

0 · Reply

noname10000 Jun. 20 at 1:33 PM

$SNOA nice

0 · Reply

kellyc09 Jun. 18 at 6:48 PM

$SNOA Forgot I even owned this stock it has been so bad.

2 · Reply

noname10000 Jun. 18 at 1:39 PM

$SNOA well ahead of 2028 deadline

0 · Reply

noname10000 Jun. 18 at 1:31 PM

$SNOA good resulta, cash 5.4 Mil

0 · Reply

MPetroGun Jun. 18 at 12:13 PM

$SNOA

0 · Reply

noname10000 Jun. 18 at 12:02 PM

$SNOA https://finance.yahoo.com/news/sonoma-pharmaceuticals-reports-fiscal-fourth-201000316.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW5hbmNlLnlhaG9vLmNvbS9xdW90ZS9TTk9BL25ld3MvP2d1Y2NvdW50ZXI9MQ&guce_referrer_sig=AQAAAIiumHlgS-I5AVnCq0FKvPC7DICboURUyX3Vn3RdIlRigRBYWt_OIm5U8vm6D7OAvN0Wg_U9gHqUOoUiLc6sFq6PFdzisEPaGGhTBNN9aPQcF7mKnVbIquPV1PbpLw_8zeAxXyZVSh2JHpLDP5h9g3_rblLndNRtr6NA3LzjHr2L

0 · Reply

noname10000 Jun. 18 at 11:58 AM

$SNOA

0 · Reply

noname10000 Jun. 18 at 11:49 AM

$SNOA 5 mil in cash, new products, new markets looks good for me

0 · Reply

d_risk Jun. 18 at 4:01 AM

$SNOA - Sonoma Pharmaceuticals, Inc. - 10K - Updated Risk Factors SNOA faces new risks from potential European Medical Devices Regulation noncompliance and reliance on collaborators whose commitment and capabilities may vary; capital raising and stock-related risks remain, with updated Nasdaq delisting concerns but no major changes otherwise. #Pharmaceuticals #NasdaqDelisting #CapitalRaising #CollaboratorRisk #MedicalDevicesRegulation 🟢 Added 🟠 Removed https://d-risk.ai/SNOA/10-K/2025-06-17

0 · Reply

frontiere Jun. 17 at 8:44 PM

$SNOA Sonoma ref=$2.95 — long smallish size, will add dips — good ER

1 · Reply

PSM_EmpowerTrading Jun. 17 at 7:54 PM

⌛️⏳️ potential swing ideas 💡 ✅️ $SNOA recently registered acne products in the United Kingdom, received clearance from the Medicines & Healthcare Products Regulatory agency for five products, including its hypochlorous acid-based wound irrigation solution , scar management products, wound hydrogel and skin exfoliant, company specializing in the development and production of stabilized hypochlorous acid products, these products are utilized in various applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants ✅️ $OFAL recently IPO, price $4, small float, company focuses on AI-driven architecture and global expansion 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

noname10000 Jun. 17 at 3:34 PM

$SNOA wake up honey with your magic low float

0 · Reply

jParkz Jun. 16 at 10:30 PM

News Article Expected earnings - Sonoma Pharmaceuticals Inc. https://marketwirenews.com/news-releases/expected-earnings-sonoma-pharmaceuticals-inc--6158780368165895.html $SNOA

0 · Reply

e1908 Jun. 16 at 8:26 AM

$SNOA when’s the next ER?

2 · Reply

Market Cap	4.72M
Revenue (ttm)	14.29M
Net Income (ttm)	-3.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-24.21%
Debt to Equity Ratio	0.00

Volume	12,800
Avg Vol	1,424,200
Day's Range	N/A - N/A
Shares Out	1.64M
Stochastic %K	21%
Beta	1.38
Analysts	Strong Sell
Price Target	$17.00